Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study

Archives of General Psychiatry

Volumn 59, Issue 12, 2002, Pages 1111-1118

  Stein, Dan J ^a   Versiani, Marcio ^b   Hair, Tanya ^c   Kumar, Rajinder ^d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF FLORIDA   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MALE; MULTICENTER STUDY; NAUSEA; RATING SCALE; RISK; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA; SOMNOLENCE; SWEATING; VERTIGO; VISUAL ANALOG SCALE; VOMITING; WELLBEING;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PERSONALITY ASSESSMENT; PHOBIC DISORDERS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0036895568     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.12.1111     Document Type: Article

References (36)

1. Lecrubier Y, Wittchen HU, Faravelli C, Bobes J, Patel A, Knapp M. A European perspective on social anxiety disorder. Eur Psychiatry. 2000;15:5-16.
2. Wittchen HU, Beloch E. The impact of social phobia on quality of life. Int Clin Psychopharmacol. 1996;11:15-23.
3. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: Comorbidity and morbidity in an epidemiological sample. Arch Gen Psychiatry. 1992;49:282-288.
4. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322-331.
5. Wittchen HU, Fuetsch M, Sonntag H, Müller N, Liebowitz M. Disability and quality of life in pure and comorbid social phobia: Findings from a controlled study. Eur Psychiatry. 2000;15:46-58.
6. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 1994;51:8-19.
7. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355-364.
8. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:159-168.
9. Weissman MM, Bland RC, Canino GJ, Greenwald S, Lee CK, Newman SC, Rubio-Stipec M, Wickramaratne PJ. The cross-national epidemiology of social phobia: A preliminary report. Int Clin Psychopharmacol. 1996;11:9-14.
10. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, Goetz D, Juster HR, Lin SH, Bruch MA, Marshall RD, Klein DF. Cognitive-behavioral group therapy versus phenelzine in social phobia: Long-term outcome. Depress Anxiety. 1999;10:89-98.
11. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial. JAMA. 1998;280:708-713.
12. Liebowitz MR, Schneier FR, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF. Phenelzine vs atenolol in social phobia: A placebo-controlled comparison. Arch Gen Psychiatry. 1992;49:290-300.
13. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423-428.
14. Ballenger JC, Davidson RT, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998; 59:54-60.
15. Den Boer J, Baldwin DS, Bobes J, Katschnig H, Westenberg H, Wittchen HU. Social anxiety disorder: Our current understanding. Int J Psychiatry Clin Pract. 1999; 3(suppl 3):S3-S12.
16. Davidson JR. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 1998; 59:47-53.
17. Allgulander C. Paroxetine in social anxiety disorder: A randomized placebo-controlled study. Acta Psychiatr Scand. 1999;100:193-198.
18. Baldwin DS, Bobes J, Stein DJ, Scharwachter I, Faure M. A randomised, doubleblind, placebo-controlled study of paroxetine in the treatment of social phobia/social anxiety disorder. Br J Psychiatry. 1999;175:120-126.
19. Lydiard RB, Bobes J. Therapeutic advances: Paroxetine for the treatment of social anxiety disorder. Depress Anxiety. 2000;11:99-104.
20. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, Walker JR. Paroxetine in the treatment of generalised social phobia: Open-label treatment and double-blind, placebo-controlled discontinuation. J Clin Psychopharmacol. 1996; 16:218-222.
21. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: A double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152:1368-1371.
22. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP. Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158:275-281.
23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: National Institute of Mental Health; 1976:218-222. US Dept of Health, Education, and Welfare publication ADM 76-338,
25. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22: 141-173.
26. Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale. Br J Psychiatry. 2000;176:379-386.
27. Sheehan D. The Anxiety Disease. New York, NY: Bantam; 1983:138.
28. Rief W, Fichter M. The Symptom Check List SCL-90-R and its ability to discriminate between dysthymia, anxiety disorders, and anorexia nervosa. Psychopathology. 1992;25:128-138.
29. EuroQol Group. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-61.
31. Campbell MJ, Gardner MJ. Calculating confidence intervals for some nonparametric analyses. BMJ. 1988;296:1454-1456.
32. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 1993; 8:189-195.
33. Claghorn JL, Feighner JP. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol. 1993; 13:23-27.
34. Duboff EA. Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol. 1993;13:28-33.
35. Lecrubier Y, Judge R, for the Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand. 1997;5:153-160.
36. Dunbar G, Steiner M, Bushnell WD. Long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine [abstract]. Eur Neuropsychopharmacol. 1995;5(special issue):372. Abstract P-6-11.